LAVA Therapeutics NV
LVTX1.740USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
45.77MMarket Cap
LossP/E TTM
More Details of LAVA Therapeutics NV Company
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
LAVA Therapeutics NV Info
Ticker SymbolLVTX
Company nameLAVA Therapeutics NV
IPO dateMar 25, 2021
CEOMr. Stephen A. Hurly
Number of employees34
Security typeOrdinary Share
Fiscal year-endMar 25
AddressYalelaan 60
CityUTRECHT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code3584 CM
Phone31850163100
Websitehttps://www.lavatherapeutics.com/
Ticker SymbolLVTX
IPO dateMar 25, 2021
CEOMr. Stephen A. Hurly
Company Executives of LAVA Therapeutics NV
Name
Name/Position
Position
Shareholding
Change
Mr. Hans Van Der Vliet, M.D., Ph.D.
Mr. Hans Van Der Vliet, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
77.35K
--
Ms. Amy Garabedian
Ms. Amy Garabedian
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
8.85K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
-100.00%
Ms. Maricel Montano
Ms. Maricel Montano
Non-Executive Director
Non-Executive Director
--
--
Mr. Bradley Sitko
Mr. Bradley Sitko
Non-Executive Director
Non-Executive Director
--
--
Mr. Thomas Burns
Mr. Thomas Burns
Non-Executive Director
Non-Executive Director
--
--
Ms. Mary Wadlinger
Ms. Mary Wadlinger
Non-Executive Director
Non-Executive Director
--
--
Mr. Owen Hughes
Mr. Owen Hughes
Executive Director
Executive Director
--
--
Ms. Nanna L. Lueneborg, Ph.D.
Ms. Nanna L. Lueneborg, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Dr. Guido Magni, M.D., Ph.D.
Dr. Guido Magni, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Hans Van Der Vliet, M.D., Ph.D.
Mr. Hans Van Der Vliet, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
77.35K
--
Ms. Amy Garabedian
Ms. Amy Garabedian
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
8.85K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
-100.00%
Ms. Maricel Montano
Ms. Maricel Montano
Non-Executive Director
Non-Executive Director
--
--
Mr. Bradley Sitko
Mr. Bradley Sitko
Non-Executive Director
Non-Executive Director
--
--
Mr. Thomas Burns
Mr. Thomas Burns
Non-Executive Director
Non-Executive Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Shay Capital LLC
9.69%
Redmile Group, LLC
7.89%
BML Capital Management LLC
7.49%
Sanofi SA
7.30%
Merck & Co Inc
4.37%
Other
63.27%
Shareholders
Shareholders
Proportion
Shay Capital LLC
9.69%
Redmile Group, LLC
7.89%
BML Capital Management LLC
7.49%
Sanofi SA
7.30%
Merck & Co Inc
4.37%
Other
63.27%
Shareholder Types
Shareholders
Proportion
Corporation
15.52%
Hedge Fund
10.52%
Investment Advisor
8.88%
Investment Advisor/Hedge Fund
8.11%
Individual Investor
0.86%
Venture Capital
0.08%
Other
56.03%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
45
7.48M
28.43%
-4.70M
2025Q2
48
18.32M
69.64%
-2.74M
2025Q1
59
22.25M
84.60%
-1.27M
2024Q4
61
18.80M
71.50%
-11.80K
2024Q3
56
15.93M
60.60%
-3.34M
2024Q2
58
16.07M
61.13%
-4.19M
2024Q1
58
16.06M
61.10%
-4.38M
2023Q4
51
18.10M
68.85%
+283.15K
2023Q3
52
18.00M
68.48%
-418.56K
2023Q2
55
18.03M
68.58%
-1.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Shay Capital LLC
2.60M
9.87%
+2.60M
--
Sep 19, 2025
Redmile Group, LLC
2.07M
7.89%
--
--
Jun 30, 2025
BML Capital Management LLC
1.97M
7.49%
+10.00K
+0.51%
Jun 30, 2025
Sanofi SA
1.92M
7.3%
--
--
Jun 30, 2025
Merck & Co Inc
1.15M
4.37%
--
--
Jun 30, 2025
Cooperatieve Gilde Healthcare IV UA
5.42M
20.61%
--
--
Sep 02, 2025
Rangeley Capital LLC
27.07K
0.1%
+27.07K
--
Jun 30, 2025
Hurly (Stephen A.)
151.80K
0.58%
+146.80K
+2935.98%
Sep 02, 2025
PNC Investments LLC
65.00K
0.25%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AltShares Event-Driven ETF
0%
AltShares Event-Driven ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of LAVA Therapeutics NV?
The top five shareholders of LAVA Therapeutics NV are:
Shay Capital LLC holds 2.60M shares, accounting for 9.87% of the total shares.
Redmile Group, LLC holds 2.07M shares, accounting for 7.89% of the total shares.
BML Capital Management LLC holds 1.97M shares, accounting for 7.49% of the total shares.
Sanofi SA holds 1.92M shares, accounting for 7.30% of the total shares.
Merck & Co Inc holds 1.15M shares, accounting for 4.37% of the total shares.
Shay Capital LLC holds 2.60M shares, accounting for 9.87% of the total shares.
Redmile Group, LLC holds 2.07M shares, accounting for 7.89% of the total shares.
BML Capital Management LLC holds 1.97M shares, accounting for 7.49% of the total shares.
Sanofi SA holds 1.92M shares, accounting for 7.30% of the total shares.
Merck & Co Inc holds 1.15M shares, accounting for 4.37% of the total shares.
What are the top three shareholder types of LAVA Therapeutics NV?
The top three shareholder types of LAVA Therapeutics NV are:
Shay Capital LLC
Redmile Group, LLC
BML Capital Management LLC
Shay Capital LLC
Redmile Group, LLC
BML Capital Management LLC
How many institutions hold shares of LAVA Therapeutics NV (LVTX)?
As of 2025Q3, 45 institutions hold shares of LAVA Therapeutics NV, with a combined market value of approximately 7.48M, accounting for 28.43% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -41.22%.
What is the biggest source of revenue for LAVA Therapeutics NV?
In --, the -- business generated the highest revenue for LAVA Therapeutics NV, amounting to -- and accounting for --% of total revenue.
